Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Apellis Pharmaceuticals, Inc. APLS
$88.21
-$0.33 (-0.37%)
На 18:00, 12 мая 2023
-13.93%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
10281841500.00000000
-
week52high
94.45
-
week52low
34.09
-
Revenue
75422000
-
P/E TTM
-16
-
Beta
1.22249100
-
EPS
-6.16000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 мая 2023 г. в 20:00
Описание компании
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Oppenheimer | Outperform | Outperform | 18 авг 2022 г. |
| Raymond James | Strong Buy | Strong Buy | 09 авг 2022 г. |
| Goldman Sachs | Buy | Buy | 09 авг 2022 г. |
| Credit Suisse | Neutral | Neutral | 09 авг 2022 г. |
| Citigroup | Buy | Buy | 20 июл 2022 г. |
| Wedbush | Neutral | Neutral | 12 сент 2022 г. |
| Stifel | Buy | Buy | 08 сент 2022 г. |
| Raymond James | Strong Buy | Strong Buy | 18 окт 2022 г. |
| JP Morgan | Overweight | Overweight | 15 ноя 2022 г. |
| Jefferies | Hold | Buy | 10 ноя 2022 г. |
| Credit Suisse | Neutral | Neutral | 08 ноя 2022 г. |
| Wells Fargo | Equal-Weight | Overweight | 03 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Dunlop A. Sinclair | D | 132297 | 500 | 01 февр 2023 г. |
| Eisele Jeffrey | D | 46468 | 883 | 30 янв 2023 г. |
| Lewis Karen | D | 36459 | 883 | 30 янв 2023 г. |
| Watson David O. | D | 166439 | 551 | 27 янв 2023 г. |
| Sullivan Timothy Eugene | D | 124211 | 551 | 27 янв 2023 г. |
| Townsend Adam J. | D | 67932 | 551 | 27 янв 2023 г. |
| SCHEIBLER LUKAS | D | 61150 | 542 | 27 янв 2023 г. |
| Lewis Karen | D | 37342 | 367 | 27 янв 2023 г. |
| Nicholson Nur | D | 54442 | 551 | 27 янв 2023 г. |
| Eisele Jeffrey | D | 47351 | 367 | 27 янв 2023 г. |
Новостная лента
Apellis Pharmaceuticals, Inc. (APLS) Q1 2023 Earnings Call Transcript
Seeking Alpha
06 мая 2023 г. в 10:56
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Meredith Kaya - Senior Vice President, Investor Relations and Strategic Finance Dr. Cedric Francois - Co-Founder and CEO Adam Townsend - Chief Commercial Officer Dr. Caroline Baumal - Chief Medical Officer Tim Sullivan - Chief Financial Officer Conference Call Participants Madhu Kumar - Goldman Sachs Jon Miller - Evercore Tazeen Ahmad - BofA Anupam Rama - JPMorgan Colleen Kusy - Baird Yigal Nochomovitz - Citigroup Steven Seedhouse - Raymond James Phil Nadeau - TD Cowen Justin Kim - Oppenheimer Derek Archila - Wells Fargo Eliana Merle - UBS Annabel Samimy - Stifel Joseph Stringer - Needham & Company Douglas Tsao - H.C. Wainwright Operator Good day and thank you for standing-by.
Apellis (APLS) Q1 Earnings Miss, Empaveli & Syfovre Fuel Growth
Zacks Investment Research
05 мая 2023 г. в 10:40
Apellis Pharmaceuticals' (APLS) loss in the first quarter is wider than estimates. Empaveli and Syfovre boost product revenues for the company.
Top-Notch Biotech Apellis Soars After New Drug Obliterates Sales Views
Investors Business Daily
05 мая 2023 г. в 09:36
Apellis' new eye drug, Syfovre, crushed expectations in its first quarter post launch, putting APLS stock on track to open at a record high. The post Top-Notch Biotech Apellis Soars After New Drug Obliterates Sales Views appeared first on Investor's Business Daily.
Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
04 мая 2023 г. в 19:01
Apellis Pharmaceuticals, Inc. (APLS) came out with a quarterly loss of $1.56 per share versus the Zacks Consensus Estimate of a loss of $1.42. This compares to loss of $1.42 per share a year ago.
Apellis Pharmaceuticals to Present at the Bank of America Securities 2023 Healthcare Conference
GlobeNewsWire
03 мая 2023 г. в 07:00
WALTHAM, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will present at the Bank of America Securities 2023 Healthcare Conference on Wednesday, May 10, 2023, at 3:40 p.m. PT.